Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) E10: ¥1.68 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600211 Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
94 GF Score
Price ¥39.30
GF Value ¥40.53
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Tibet Rhodiola Pharmaceutical Holding Co E10?

Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211 +1.39% 94 E10 is ¥1.68 as of Mar. 2026. GuruFocus rates SHSE:600211 with a GF Score™ of 94/100 and a GF Value™ of ¥40.53 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Tibet Rhodiola Pharmaceutical Holding Co's adjusted earnings per share data for the three months ended in Mar. 2026 was ¥0.930. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ¥1.68 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Tibet Rhodiola Pharmaceutical Holding Co's average E10 Growth Rate was 20.00% per year. During the past 3 years, the average E10 Growth Rate was 28.50% per year. During the past 5 years, the average E10 Growth Rate was 24.20% per year. During the past 10 years, the average E10 Growth Rate was 36.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Tibet Rhodiola Pharmaceutical Holding Co was 102.10% per year. The lowest was 18.60% per year. And the median was 28.50% per year.

As of today (2026-07-14), Tibet Rhodiola Pharmaceutical Holding Co's current stock price is ¥39.30. Tibet Rhodiola Pharmaceutical Holding Co's E10 for the quarter that ended in Mar. 2026 was ¥1.68. Tibet Rhodiola Pharmaceutical Holding Co's Shiller PE Ratio of today is 23.39.

During the past 13 years, the highest Shiller PE Ratio of Tibet Rhodiola Pharmaceutical Holding Co was 470.70. The lowest was 21.19. And the median was 49.08.


Tibet Rhodiola Pharmaceutical Holding Co  (SHSE:600211) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Tibet Rhodiola Pharmaceutical Holding Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=39.30/1.68
=23.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Tibet Rhodiola Pharmaceutical Holding Co was 470.70. The lowest was 21.19. And the median was 49.08.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Tibet Rhodiola Pharmaceutical Holding Co E10 Related Terms


Tibet Rhodiola Pharmaceutical Holding Co E10 Historical Data

* Premium members only.

The historical data trend for Tibet Rhodiola Pharmaceutical Holding Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tibet Rhodiola Pharmaceutical Holding Co E10 Chart

Tibet Rhodiola Pharmaceutical Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.75 0.99 1.32 1.59

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.40 1.49 1.53 1.59 1.68

SHSE:600211 vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Rhodiola Pharmaceutical Holding Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Rhodiola Pharmaceutical Holding Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Tibet Rhodiola Pharmaceutical Holding Co's Shiller PE Ratio falls into.


SHSE:600211
94GF Score
Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tibet Rhodiola Pharmaceutical Holding Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tibet Rhodiola Pharmaceutical Holding Co's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.93/116.3033*116.3033
=0.930

Current CPI (Mar. 2026) = 116.3033.

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data

per share eps CPI Adj_EPS
201606 0.155 101.400 0.178
201609 0.214 102.400 0.243
201612 0.302 102.600 0.342
201703 0.203 103.200 0.229
201706 0.000 103.100 0.000
201709 0.236 104.100 0.264
201712 0.300 104.500 0.334
201803 0.209 105.300 0.231
201806 0.187 104.900 0.207
201809 0.308 106.600 0.336
201812 -0.048 106.500 -0.052
201903 0.214 107.700 0.231
201906 0.265 107.700 0.286
201909 0.354 109.800 0.375
201912 0.308 111.200 0.322
202003 0.562 112.300 0.582
202006 0.285 110.400 0.300
202009 0.308 111.700 0.321
202012 0.146 111.500 0.152
202103 0.485 112.662 0.501
202106 0.438 111.769 0.456
202109 0.377 112.215 0.391
202112 -0.654 113.108 -0.672
202203 0.538 114.335 0.547
202206 0.277 114.558 0.281
202209 0.562 115.339 0.567
202212 -0.231 115.116 -0.233
202303 0.938 115.116 0.948
202306 0.912 114.558 0.926
202309 0.800 115.339 0.807
202312 -0.170 114.781 -0.172
202403 0.970 115.227 0.979
202406 0.960 114.781 0.973
202409 0.530 115.785 0.532
202412 0.800 114.893 0.810
202503 0.840 115.116 0.849
202506 0.920 114.907 0.931
202509 0.480 115.471 0.483
202512 0.670 115.832 0.673
202603 0.930 116.303 0.930

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ¥1.68 mean?
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a E10 of ¥1.68 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors.
Is Tibet Rhodiola Pharmaceutical Holding Co's E10 too high?
Tibet Rhodiola Pharmaceutical Holding Co's current E10 is ¥1.68. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's E10 compare to ZTS and UTHR?
Tibet Rhodiola Pharmaceutical Holding Co's E10 of ¥1.68 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. Tibet Rhodiola Pharmaceutical Holding Co's current E10 is ¥1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.53, compared to a current price of ¥39.30 — trading 3% below its estimated fair value. The current E10 is ¥1.68. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current E10 is ¥1.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?

Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued. The current stock price of ¥39.30 is trading 3% below its estimated GF Value™ of ¥40.53. GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.

Key valuation signals for SHSE:600211:

  • E10: ¥1.68
  • GF Value™: ¥40.53 vs. price of ¥39.30 (3% below fair value)
  • GF Score™: 94/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tibet Rhodiola Pharmaceutical Holding Co Business Description

Address No. 3 Guangzhou Road, Area A, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score

Get the complete analysis for SHSE:600211

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥39.30
Price
¥40.53
GF Value